[go: up one dir, main page]

WO2014081712A3 - Methods of treating a disease or disorder associated with bruton's tyrosine kinase - Google Patents

Methods of treating a disease or disorder associated with bruton's tyrosine kinase Download PDF

Info

Publication number
WO2014081712A3
WO2014081712A3 PCT/US2013/070772 US2013070772W WO2014081712A3 WO 2014081712 A3 WO2014081712 A3 WO 2014081712A3 US 2013070772 W US2013070772 W US 2013070772W WO 2014081712 A3 WO2014081712 A3 WO 2014081712A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
disease
disorder associated
methods
bruton
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/070772
Other languages
French (fr)
Other versions
WO2014081712A2 (en
Inventor
Tom Daniel
Kenichi Takeshita
Kenneth Foon
Jay Mei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Avilomics Research Inc
Original Assignee
Celgene Avilomics Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Avilomics Research Inc filed Critical Celgene Avilomics Research Inc
Priority to EP13857254.0A priority Critical patent/EP2922827A4/en
Publication of WO2014081712A2 publication Critical patent/WO2014081712A2/en
Anticipated expiration legal-status Critical
Publication of WO2014081712A3 publication Critical patent/WO2014081712A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK. In particular, the invention provides a method of treating, stabilizing or lessening the severity or progression of one or more diseases and conditions associated with BTK comprising administering to a patient in need thereof comprising administering to a patient in need thereof, Compound 1 (N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl) acrylamide) or a pharmaceutically acceptable salt thereof, and an anti-CD20 antibody.
PCT/US2013/070772 2012-11-20 2013-11-19 Methods of treating a disease or disorder associated with bruton's tyrosine kinase Ceased WO2014081712A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13857254.0A EP2922827A4 (en) 2012-11-20 2013-11-19 Methods of treating a disease or disorder associated with bruton's tyrosine kinase

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261728701P 2012-11-20 2012-11-20
US61/728,701 2012-11-20
US201361870720P 2013-08-27 2013-08-27
US61/870,720 2013-08-27

Publications (2)

Publication Number Publication Date
WO2014081712A2 WO2014081712A2 (en) 2014-05-30
WO2014081712A3 true WO2014081712A3 (en) 2015-07-16

Family

ID=50776662

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/070772 Ceased WO2014081712A2 (en) 2012-11-20 2013-11-19 Methods of treating a disease or disorder associated with bruton's tyrosine kinase

Country Status (3)

Country Link
EP (1) EP2922827A4 (en)
TW (1) TW201427667A (en)
WO (1) WO2014081712A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011152351A1 (en) 2010-05-31 2011-12-08 小野薬品工業株式会社 Purinone derivative
LT2786996T (en) 2011-11-29 2017-01-10 Ono Pharmaceutical Co., Ltd. Purinone derivative hydrochloride
JP2016509012A (en) 2013-02-08 2016-03-24 セルジーン アビロミクス リサーチ， インコーポレイテッド ERK inhibitors and their use
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CN113995843A (en) * 2013-11-07 2022-02-01 豪夫迈·罗氏有限公司 Combination therapy of anti-CD 20 antibodies with BTK inhibitors
EP3122360B1 (en) 2014-03-25 2020-06-17 ONO Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
US10239879B2 (en) 2015-04-09 2019-03-26 Ono Pharmaceutical Co., Ltd. Process for producing purinone derivative
JP7642531B2 (en) 2018-05-11 2025-03-10 ビーム セラピューティクス インク． Methods for replacing pathogenic amino acids using a programmable base editor system

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100249092A1 (en) * 2008-06-27 2010-09-30 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
US20120077832A1 (en) * 2010-08-10 2012-03-29 Avila Therapeutics, Inc. Besylate salt of a btk inhibitor
US20120087915A1 (en) * 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US8206711B2 (en) * 1998-11-09 2012-06-26 Biogen Idec Inc. Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies
WO2012100459A1 (en) * 2011-01-28 2012-08-02 广州盈升生物科技有限公司 Phosphorus substituted group-containing quinoline-like compound, its preparation process, medical composition containing the compound and application
WO2012135801A1 (en) * 2011-04-01 2012-10-04 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2536584C2 (en) * 2008-06-27 2014-12-27 Авила Терапьютикс, Инк. Heteroaryl compounds and using them
TW201325593A (en) * 2011-10-28 2013-07-01 Celgene Avilomics Res Inc Methods of treating a BRUTON'S tyrosine kinase disease or disorder

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206711B2 (en) * 1998-11-09 2012-06-26 Biogen Idec Inc. Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies
US20100249092A1 (en) * 2008-06-27 2010-09-30 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
US20120087915A1 (en) * 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US20120077832A1 (en) * 2010-08-10 2012-03-29 Avila Therapeutics, Inc. Besylate salt of a btk inhibitor
WO2012100459A1 (en) * 2011-01-28 2012-08-02 广州盈升生物科技有限公司 Phosphorus substituted group-containing quinoline-like compound, its preparation process, medical composition containing the compound and application
WO2012135801A1 (en) * 2011-04-01 2012-10-04 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2922827A4 *

Also Published As

Publication number Publication date
EP2922827A2 (en) 2015-09-30
WO2014081712A2 (en) 2014-05-30
EP2922827A4 (en) 2016-06-08
TW201427667A (en) 2014-07-16

Similar Documents

Publication Publication Date Title
WO2014081712A3 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
WO2014081714A3 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
PH12018500401B1 (en) Antibodies specific for tgf-beta
WO2015048662A3 (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
HK1198443A1 (en) Heterocyclic compounds and uses thereof
EA201391416A1 (en) NEW CONNECTIONS AS PROTEINKINASE MODULATORS
WO2017097723A3 (en) Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
EP3060251A4 (en) Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
CY1121421T1 (en) PHARMACEUTICAL FORMS
MY177742A (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
PH12014500468A1 (en) Heterocyclic compounds and uses thereof
EA201691399A1 (en) METHODS AND READY MEDICATION FORMS FOR THE TREATMENT OF ALZHEYMER
HK1207069A1 (en) Heterocyclic compounds and uses thereof
MX380928B (en) KRAS G12C INHIBITORS.
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
EA201790267A1 (en) NEW KINAZ MODULATORS
HK1221168A1 (en) Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4- ylamino)phenyl)acrylamide for treating cancer
AR088570A1 (en) METHODS TO TREAT AN ILLNESS OR DISORDER RELATED TO BRUTON TYROSINE KINASE
WO2015001504A3 (en) Antibody formulations and methods
HK1211831A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EA201492040A1 (en) BICYCLICALLY SUBSTITUTED URACILES AND THEIR APPLICATION
CL2012001270A1 (en) Compound 4-methyl-n- [3- (4-methyl-1h-imidazol-1-yl) -5- (trifluoromethyl) phenyl] -3 - [(4-pyridin-3-ylpyrimidin-2-yl) amino] benzamide (nilotinib) for the treatment of a proliferative disorder or other conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase, administered orally dispersed in an apple sauce.
EA201401353A1 (en) BIOMARKERS TO DETERMINE AN EFFECTIVE RESPONSE RESPONSE TO THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
MX355129B (en) Compounds and methods for treating aberrant adrenocartical cell disorders.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13857254

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013857254

Country of ref document: EP